Lung Cancer News

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

CHICAGO — ChatGPT can be used to develop next-generation sequencing reports that outline treatment strategies for patients who have non-small cell lung cancer with driver oncogenes, according to results presented at ASCO Annual Meeting.

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.

CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the randomized phase 3 IND.227/KEYNOTE-483 trial.

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

CHICAGO — A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria.

CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADAURA trial presented at ASCO Annual Meeting.